Chimerism

Chimerism is a biological condition in which an individual possesses two or more genetically distinct cell populations originating from different zygotes (StatPearls, 2023). In a clinical context, it most frequently occurs following hematopoietic stem cell transplantation (HSCT) or solid organ transplantation, where the recipient's immune system is partially or fully replaced by donor-derived cells (NIH National Cancer Institute). Chimerism is not a molecular target such as a receptor, enzyme, or transporter; instead, it is a complex physiological state used as a diagnostic and prognostic indicator of transplant success and immune reconstitution. Monitoring chimerism levels is essential for detecting early signs of graft rejection or disease relapse, particularly in hematologic malignancies (PubMed, PMID: 15743717). While various pharmacological agents, including immunosuppressants like Tacrolimus and conditioning agents like Busulfan, are used to achieve and maintain a chimeric state, they do so by targeting specific molecular pathways (e.g., calcineurin inhibition or DNA alkylation) rather than the phenomenon of chimerism itself. Consequently, while chimerism is a critical focus of transplant medicine, it represents a systemic outcome of therapy rather than a druggable molecule.

Other names

Genetic chimerismMixed chimerismMicrochimerismTetragametic chimerismHematopoietic chimerism

Not applicable as chimerism is a biological state rather than a molecular target; however, it is managed via lymphodepletion and immunosuppression to allow donor cell engraftment.